Real-World Evidence Solutions for NHS, Universities, Pharma & CROs
Real-World Evidence (RWE) bridges the gap between clinical trials and everyday clinical practice, providing robust evidence from real patient data to support drug development, regulatory submissions, and healthcare decision-making.
What We Do
- Design and deliver RWE studies using NHS, CPRD, SAIL and international datasets
- Generate evidence for market access, HTA submissions and NICE appraisals
- Support post-market surveillance and drug safety monitoring
- Conduct comparative effectiveness research across patient populations
- Develop study protocols compliant with UK, EU and US regulatory standards
- Integrate RCT data with real-world evidence to bridge trial populations and everyday clinical practice.
Data Sources We Use
- CPRD Aurum & Gold: primary care data from GP practices across the UK
- Hospital Episode Statistics (HES): every hospital admission, outpatient appointment and A&E attendance in England
- GP records: primary care data from EMIS, SystmOne and Vision systems
- Linked primary and secondary care datasets: providing the complete patient journey from GP to hospital
- SAIL Databank: Wales population data
- NHS Digital datasets: national linked health data
- US Health datasets: for international RWE studies
- Disease registries and biobanks: condition-specific and genomic data
- Randomised Controlled Trial (RCT) data: integrated with RWE for complete evidence generation
Who We Support
- Pharmaceutical and biotech companies
- NHS organisations and ICBs
- Contract Research Organisations (CROs)
- Academic and university research groups
- US healthcare organisations and research institutions
What You Get
- Regulatory-grade RWE study reports
- Validated analytical outputs
- Publication-ready manuscripts
- Evidence packages for HTA and market access
- Integrated RWE and trial evidence summaries